Introducing TissueCypher™ Barrett’s Esophagus Assay

The first application of Cernostics' TissueCypher™ Platform


Cernostics' lead product under development, TissueCypher™ Barrett’s Esophagus Assay, uses whole slide digital imaging technology to produce comprehensive risk prediction for the development of esophageal cancer in patients with Barrett's Esophagus.  The TissueCypher™ Barrett’s Esophagus Assay will focus on eliminating uncertainty related to the treatment of Barrett's Esophagus and will provide actionable information to doctors and patients.


Esophageal cancer is one of the fastest growing cancers (by incidence) in the world.  The incidence of this once rare cancer has increased by more than 500% since the 1970s1.  Esophageal cancer remains highly lethal, with a 5 year survival rate of 17%2.  This dramatic increase in esophageal cancer incidence closely tracks with increases in obesity and chronic gastrointestinal reflux (GERD) in western countries, and these are major risk factors for the development of esophageal cancer.


Chronic reflux in the esophagus causes changes to the molecular and cellular features of the esophagus, which often results in a condition called Barrett’s Esophagus.  Barrett's is a serious complication of GERD, and a risk factor for the development of esophageal cancer. Today, gastroenterologists cannot adequately determine which patients with Barrett's Esophagus will progress to esophageal cancer.  As a result, patients with Barrett's must undergo regular surveillance endoscopies to check the status of the condition.  New diagnostic and prognostic tests are needed to provide actionable information to physicians and patients managing Barrett's Esophagus.


Contact Us to learn more about the TissueCypher™ Barrett’s Esophagus Assay.

Pohl, H. & Welch, H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97, 142-6 (2005).
2 Cancer Facts & Figures 2013, American Cancer Society
Customer Service

Mon-Fri 9am-5pm (EST)